VIP — Vasoactive Intestinal Peptide

5mg Vial

10mg Vial

2 September 2026Updated 2 September 2026

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for VIP — Vasoactive Intestinal Peptide.

Create free account Member login

Full range of benefits for VIP — Vasoactive Intestinal Peptide

Vasodilation via cAMP-mediated relaxation of vascular smooth muscle

Bronchodilation through relaxation of airway smooth muscle

Anti-inflammatory: downregulates TNF-α and IL-6 in some models

Immunomodulation: promotes IL-10 and shifts Th1/Th2 responses

Supports pulmonary endothelial barrier integrity and reduces edema

Neuroprotective actions: promotes neuronal survival and repair signaling

Stimulates intestinal fluid secretion and regulates gut motility

Inhibits gastric acid secretion and promotes pancreatic bicarbonate

Reduces mast cell degranulation and histamine release in models

Modulates cardiac and systemic hemodynamics via cAMP pathways

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 16 known interactions

Synergistic(4)Compatible(4)Monitor(4)Avoid(4)

Use with professional oversight

Antihypertensives/vasodilators (ACE inhibitors, calcium channel blockers, nitrates)

Because VIP produces vasodilation and can lower blood pressure, monitor blood pressure and adjust antihypertensive dosing to avoid symptomatic hypotension.

Antidiabetic agents (insulin, sulfonylureas)

VIP can influence islet hormone secretion and glucose homeostasis, so monitor blood glucose and adjust antidiabetic therapy as needed.

Diuretics (loop and thiazide diuretics)

Volume depletion from diuretics may exacerbate VIP-induced hypotension, so monitor volume status, electrolytes and orthostatic blood pressure.

Cardiac rate-modifying drugs (beta-blockers, digoxin)

VIP-related reflex tachycardia or direct chronotropic effects warrant monitoring of heart rate and rhythm when combined with agents that alter cardiac conduction or rate.

All interaction categories

Synergistic (4)

Beta-2 adrenergic agonists (e.g., salbutamol): Additive bronchodilation via complementary cAMP-mediated smooth muscle relaxation, which can enhance airway-opening effects when co-administered with VIP.
PDE inhibitors (e.g., theophylline, roflumilast): Phosphodiesterase inhibition prolongs intracellular cAMP signalling and can potentiate VIP's bronchodilatory and vasodilatory actions, increasing therapeutic effect.
Inhaled corticosteroids (e.g., budesonide): Concomitant anti-inflammatory effects are complementary to VIP's immunomodulatory actions and may produce enhanced control of airway inflammation.
Muscarinic antagonists (e.g., ipratropium, tiotropium): Non-overlapping mechanisms for bronchodilation provide complementary symptomatic benefit when combined with VIP in obstructive airway disease.

Compatible (4)

Proton pump inhibitors (e.g., omeprazole): No known pharmacodynamic or metabolic interaction with VIP; coadministration is generally neutral and does not require special adjustments.
Beta-lactam antibiotics (e.g., amoxicillin): Antibacterial agents of this class do not affect VIP pharmacology or clearance and are considered compatible for concomitant use.
Statins (e.g., atorvastatin): No direct interaction is expected between HMG-CoA reductase inhibitors and VIP, permitting routine coadministration under standard monitoring.
Topical agents (local dermal therapies): Locally applied topical medications have minimal systemic interaction with VIP and are generally neutral when used concurrently.

Monitor (4)

Antihypertensives/vasodilators (ACE inhibitors, calcium channel blockers, nitrates): Because VIP produces vasodilation and can lower blood pressure, monitor blood pressure and adjust antihypertensive dosing to avoid symptomatic hypotension.
Antidiabetic agents (insulin, sulfonylureas): VIP can influence islet hormone secretion and glucose homeostasis, so monitor blood glucose and adjust antidiabetic therapy as needed.
Diuretics (loop and thiazide diuretics): Volume depletion from diuretics may exacerbate VIP-induced hypotension, so monitor volume status, electrolytes and orthostatic blood pressure.
Cardiac rate-modifying drugs (beta-blockers, digoxin): VIP-related reflex tachycardia or direct chronotropic effects warrant monitoring of heart rate and rhythm when combined with agents that alter cardiac conduction or rate.

Avoid (4)

Nitrates (e.g., nitroglycerin, isosorbide dinitrate): Concomitant use may produce profound additive vasodilation and symptomatic hypotension, so combine only after careful clinical evaluation and monitoring.
Phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil): Concurrent administration can lead to excessive vasodilation and syncope risk, therefore requires careful assessment and usually avoidance or close supervision.
Calcineurin inhibitors (cyclosporine, tacrolimus): Because VIP has immunomodulatory effects, combining with potent immunosuppressants may increase infection risk and warrants risk–benefit assessment and surveillance.
Live attenuated vaccines: VIP's immunomodulatory properties could theoretically alter vaccine response or infection risk, so assess timing and necessity of live vaccines before coadministration.